The product is being launched in August 2023
The approved product has an estimated market size of around US$ 210 million for the twelve months ending May 2023
Thiamine Hydrochloride Injection USP had estimated annual sales of USD 35 million in the U.S.
Granules now has a total of 58 ANDA approvals from US FDA
The product is expected to be launched in June 2023
Brimonidine Tartrate Ophthalmic Solution is an alpha adrenergic receptor agonist indicated for the reduction of elevated intraocular pressure
Prazosin Hydrochloride Capsule is indicated for the treatment of hypertension, to lower blood pressure
The approved product is indicated for the treatment of adult patients with Multiple myeloma, in combination with Dexamethasone
Subscribe To Our Newsletter & Stay Updated